
	Avaxia is a leader in the growing field of gut-targeted therapeutics &mdash; orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia&rsquo;s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
